KOSDAQBiotech & Pharma140410

Mezzion Pharma

₩68,000▼ 7.61%2026-10-02 close

Market Cap

₩2.1T

Turnover

₩10.9B

Volume

160,000 shares

Shares out.

30.6M

PER

—

PBR

50.7×

EPS

-₩910

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

A single-pipeline biotech approaching trial readout

Mezzion is a clinical-stage company whose revenue comes almost entirely from a small feed-distribution business, with essentially all of its enterprise value tied to udenafil's confirmatory Phase 3 (FUEL-2) for Fontan patients and the regulatory path that follows.

1
The company is developing JURVIGO (udenafil) as a first therapy for patients living with Fontan circulation after single-ventricle congenital heart disease, running the confirmatory Phase 3 FUEL-2 across the United States and Asia.
2
At a December 2025 investor briefing the sixth interim analysis showed a standard deviation of 2.490 on the primary endpoint, peak oxygen uptake, below the 4.0 assumed at design, and the company decided to keep the original design without enrolling more patients.
3
In 2025 revenue was 7.9 billion won with a 16.8 billion won operating loss and a 34.9 billion won net loss, and the revenue base itself shrank sharply after a production facility was sold in 2023.
4
At end-2025 equity of 17.2 billion won against liabilities of 80.8 billion won pushed the debt-to-equity ratio to 470.1%, and operating cash flow has been an outflow for four consecutive years.
5
Because most development spending has been capitalized as an intangible asset, the possibility of a large impairment charge in the event of regulatory failure is a standing risk.

Business structure

Mezzion began in 2002 as Dong-A PharmTech, founded around in-licensed rights to udenafil from Dong-A Pharmaceutical (now Dong-A ST).

Chairman Park Dong-hyun set up the company after in-licensing udenafil, the active ingredient of Zydena, an erectile dysfunction drug approved by Dong-A ST, and Mezzion holds in-licensed rights for the United States, Russia, Canada and Mexico.

Its core asset is a single program: it is developing JURVIGO (udenafil) as the first therapy for patients born with single-ventricle congenital heart disease who live on Fontan circulation, and is running the global confirmatory Phase 3 FUEL-2 with enrollment in the United States and Asia.

The Fontan operation is performed around age two to reduce mortality in single-ventricle patients, but it is not a cure; cardiac function declines with age and complications such as heart failure and reduced exercise capacity follow.

Reported revenue comes not from drugs but from a domestic animal-feed distribution operation.

After a board decision in August 2023 to sell the feed production facility, manufactured-product sales disappeared and only merchandise sales remain; management has described the feed unit as a business kept largely to satisfy listing-maintenance requirements.

Research and development leans on outside infrastructure rather than in-house scientists: the company has stated in its filings that it does not perform early-stage discovery itself, has no internal research staff and conducts R&D through external consultants.

Clinical and regulatory execution sits with the United States subsidiary; cumulative funding to Mezzion Pharmaceuticals, established in 2016, is understood to have reached 163.4 billion won over eight years through end-2024. The competitive setup differs from ordinary pharmaceutical rivalry.

According to the company, no FDA-approved therapy exists for the Fontan population, which faces high morbidity and mortality. That also means there is no comparable precedent to lean on and, in effect, no backup pipeline if this one fails.

Earnings trend

Quarterly revenue · Operating profit

₩1.7B-₩3.5B25Q2₩2.1B-₩4.7B25Q3₩2.1B-₩5.1B25Q4₩2B-₩4.6B26Q1₩2.2B-₩4.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩30.7B-₩23.3B2022₩31.7B-₩14.5B2023₩8.6B-₩14.3B2024₩7.9B-₩16.8B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.7B	-₩3.5B	−203.4%
2025Q3	₩2.1B	-₩4.7B	−218.6%
2025Q4	₩2.1B	-₩5.1B	−242.3%
2026Q1	₩2B	-₩4.6B	−226.4%
2026Q2	₩2.2B	-₩4.5B	−206.3%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩30.7B	-₩23.3B	-₩36.3B	−75.9%	−138.3%	105.9%
2023	₩31.7B	-₩14.5B	-₩12.7B	−45.7%	−20.7%	50.0%
2024	₩8.6B	-₩14.3B	-₩19.5B	−166.0%	−42.3%	60.6%
2025	₩7.9B	-₩16.8B	-₩34.9B	−212.0%	−203.1%	470.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

The direction of earnings has been loss-making for four straight years, but the nature of revenue changed midway.

Revenue fell from 30.7 billion won in 2022 and 31.7 billion won in 2023 to 8.6 billion won in 2024 and 7.9 billion won in 2025, tracking the structural shift after the August 2023 sale of the feed production facility, which removed manufactured-product sales and left only merchandise sales.

Operating loss narrowed from 23.3 billion won in 2022 to 14.5 billion won in 2023 and 14.3 billion won in 2024, then widened again to 16.8 billion won in 2025; with a much smaller revenue base, the operating margin deteriorated from -45.7% in 2023 to -212.0% in 2025.

Net loss grew from 12.7 billion won in 2023 to 19.5 billion won in 2024 and 34.9 billion won in 2025, with the 2025 net loss more than double the operating loss.

On a quarterly basis, revenue stayed near 2 billion won, from 1.7 billion won in 2Q25 to 2.2 billion won in 2Q26, while operating loss hovered in the 4.5 to 5.1 billion won range: 4.7 billion won in 3Q25, 5.1 billion won in 4Q25, 4.6 billion won in 1Q26 and 4.5 billion won in 2Q26.

Net results, by contrast, swung violently, from a 24.6 billion won loss in 4Q25 to a 7.7 billion won profit in 2Q26, which points to items unrelated to operations.

The company has indeed explained on its website that the charge reflected a fair-value increase arising when the share price exceeded the conversion price of its convertible bonds, that it was a non-cash book loss, and that conversion into shares would move the amount into equity and improve the capital structure.

The balance sheet changed materially in 2025.

Equity fell from 61.4 billion won in 2023 and 46.1 billion won in 2024 to 17.2 billion won in 2025 while liabilities rose from 27.9 billion won to 80.8 billion won, lifting the debt-to-equity ratio from 60.6% to 470.1%; operating cash flow was negative for four straight years at -12.1 billion won in 2022, -11.0 billion won in 2023, -18.5 billion won in 2024 and -16.6 billion won in 2025.

Industry analysis

The Fontan indication is a textbook unmet-need rare disease market. With no FDA-approved therapy available, the patient population faces high morbidity and mortality, a framing shared by the company and participating clinicians, so this is not a setting of head-to-head price competition with established products.

The market is, however, small in absolute terms. The company has previously cited roughly 35,000 Fontan surgery patients in the United States, of whom about 25,000 aged twelve or older would be treatment candidates. Pricing strategy follows orphan-drug convention.

At its December 2025 briefing the company said it had analyzed the expected annual cost of udenafil therapy in the United States at about 180,000 dollars. Policy incentives are another industry variable.

In December 2025 the company disclosed that it was engaging the United States Congress on reauthorization of the rare pediatric disease priority review voucher program, that it hoped to secure a voucher, recently trading on average around 150 million dollars, and that it had completed an application for the FDA's Commissioner's National Priority Voucher program.

Exclusivity rests on the dual protection typical of orphan drugs.

The company has said that seven years of market exclusivity under the Orphan Drug Act plus six months of pediatric exclusivity, together with up to five years of patent term extension under Hatch-Waxman, should extend its United States protection into the early 2040s.

Versus domestic peers, Mezzion is a concentrated single-asset story rather than a diversified pipeline, so its earnings and financing terms move with individual clinical and regulatory events more than with the sector cycle. Indication expansion would dilute that concentration, but it remains at an early stage.

Outlook

The nearest checkpoint is the trial timeline. The company has been running its second Phase 3 since October 2023 in 430 patients, expandable to 500, and as of January 2026 reporting the study was said to be scheduled to conclude in October. Management reads the interim data positively.

At a briefing on December 16, 2025, the sixth interim analysis showed a standard deviation of 2.490 on the primary efficacy endpoint of peak oxygen uptake, below the 4.0 assumed at design, and the company said the implied effect size reached 1.39 and decided not to expand enrollment, judging that statistical significance would be attainable if the observed standard deviation held.

The approval bar itself was set unusually, which is also on the record. A company official explained that the FDA indicated it would grant approval if the repeat trial produced a p-value of 0.1 or below, which is why FUEL-2 is under way. The second axis is indication expansion.

Per early August 2026 reporting, the company is extending udenafil into autosomal dominant polycystic kidney disease, and plans a Phase 2b in adult patients after preclinical work showed statistically significant reductions in renal cyst burden and blood urea nitrogen.

The company said it held pre-IND discussions with the FDA, which conveyed that existing nonclinical data and roughly two decades of accumulated clinical and safety experience with udenafil provide a basis for reviewing development in this indication.

By contrast, commercialization readiness and partnership terms are not established in public disclosure, so the timing of a new drug application refiling after trial completion and the review pathway, including whether priority review applies, form the practical fork in the road.

On funding, feed distribution revenue cannot cover research spending, so any further capital raising is a parallel item to watch.

Valuation

PER

—

PBR

50.7×

ROE

-68.3%

EPS

-₩910

BPS

₩1,281

Dividend per share

₩0

Mezzion has posted net losses across the most recent four quarters, so earnings-based multiples cannot be computed at all. On an asset basis, equity had shrunk to 17.2 billion won at end-2025, meaning the shares trade at a very large premium to accounting net assets.

In other words, the market price reflects an expected value built on the probability of udenafil's clinical success and assumptions about United States orphan pricing and patient numbers, rather than current financial statements. No dividend is paid, so there is no yield basis for comparison either.

For reference, a Small Insight Research report covered in January 2026 estimated annual United States revenue of about 760 billion won assuming pricing of roughly 180,000 dollars a year and a conservative 3,000 patients, which is one research house's assumption set and a scenario framed before approval, reimbursement and uptake are settled.

Ultimately the valuation debate turns not on multiple comparison but on the outcome of discrete events, trial completion and the regulatory process, and on the cash required until then.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Interim metrics came in better than design assumptions

The sixth interim analysis disclosed at the December 2025 briefing showed a standard deviation of 2.490 on peak oxygen uptake, below the 4.0 assumed at design. The company judged that significance would be attainable if that level held and decided not to enlarge enrollment.

Read alongside management's account that the approval bar was agreed at a p-value of 0.1 or below, the statistical headroom looks comparatively wide. That said, an interim analysis is a blinded tally and is not the same as a final result.

An indication with no approved rival and long exclusivity

The company states that the Fontan population has no FDA-approved therapy. It has said that seven years of orphan market exclusivity plus six months of pediatric exclusivity, together with patent term extension, should carry United States protection into the early 2040s.

In 2025 it announced a notice of allowance from the United States Patent and Trademark Office covering use of udenafil to improve exercise capacity in Fontan patients, including twice-daily oral dosing regardless of age and dependent claims on cardiopulmonary exercise test measures. If approval is reached, the low initial competitive pressure is the core of the bullish case.

Indication expansion and policy-incentive optionality

In August 2026 the company said it would extend udenafil into autosomal dominant polycystic kidney disease and pursue a Phase 2b in adult patients. That disease is reported to affect roughly 140,000 patients in the United States, with tolvaptan cited as the only current therapy.

The company also disclosed in December 2025 that it was engaging Congress on reauthorization of the rare pediatric disease priority review voucher program and had completed an application to the FDA's expedited review program. If they work, these items reduce single-pipeline dependence, but all remain early-stage plans.

Bear factors

The revenue base is unrelated to the drug and very small

Revenue of 7.9 billion won in 2025 was about a quarter of the 31.7 billion won in 2023, and quarterly revenue has hovered near 2 billion won, from 1.7 billion won in 2Q25 to 2.2 billion won in 2Q26.

That reflects the structure left after the 2023 sale of the feed production facility, which left only merchandise sales, with management describing the feed unit as maintained largely for listing-maintenance purposes.

With quarterly operating losses running between 4.5 and 5.1 billion won, this revenue cannot self-fund research spending. Completing the trial is therefore directly tied to external financing conditions.

Shrinking equity and a sharply higher debt ratio

Equity fell from 61.4 billion won in 2023 to 46.1 billion won in 2024 and 17.2 billion won in 2025, while liabilities rose from 27.9 billion won to 80.8 billion won, lifting the debt-to-equity ratio from 60.6% to 470.1%.

Operating cash flow was negative for four straight years from 2022 to 2025, at -12.1, -11.0, -18.5 and -16.6 billion won.

The company raised 93.0 billion won externally over the past five years, including 20.0 billion won of convertible bonds in 2021, a 50.0 billion won third-party share placement in 2023 and 23.0 billion won of fourth and fifth convertible bonds in June 2025.

Convertible-heavy funding leaves behind both potential share count growth and volatile fair-value gains and losses.

Impairment risk from capitalized development costs

According to reporting, the company has sustained its trials on external funding while capitalizing most development spending as an intangible asset, and the risk highlighted is that failure would force a large one-off impairment charge.

Since 2020, when capitalization began, the key audit matter of recognition and impairment of development costs has appeared in the annual report every year. The longer final approval takes, the larger the capitalized balance tends to grow. If clinical results disappoint, the hit to reported earnings could be severe independent of cash outflows.

Risk factors

Clinical and regulatory risk

The company has already been set back twice in the approval process.

After completing Phase 3 in December 2019 it filed in June 2020 but was challenged on the statistical significance of the primary endpoint; it refiled using a reanalysis excluding super-Fontan patients, which the FDA said was a post hoc analysis and hard to use as a basis for approval, and the application was ultimately withdrawn to run an additional trial.

If the final data again fail the agreed bar, the process could stretch out once more. The interim analysis is a blinded reference point and may differ from the final unblinded outcome.

Funding and dilution risk

With losses and operating cash outflows continuing, funding has come mainly from convertible bonds and share placements. The company has not recorded a profitable year in twenty-three years of operation, and commentary notes that mezzanine financing proceeded on expectations rather than results.

Convertible bonds generate derivative valuation swings with the share price, and as the company itself explains, conversion into shares moves the amount into equity while increasing the share count.

Factoring in approval and commercialization costs after the trial ends, whether and on what terms more capital is raised bears directly on existing holders' ownership.

Commercial execution risk

Even with approval, pricing negotiations, insurance coverage and actual prescription uptake remain in the United States orphan market. The company said it had analyzed annual treatment cost at about 180,000 dollars, but that is company analysis rather than a negotiated outcome.

Management has previously said it was preparing to recruit sales staff on the view that a direct sales network beats outsourced distribution for an orphan drug, which saves commissions but requires building an organization.

A direct model serving a small patient population carries both upfront fixed costs and uncertainty over how quickly revenue is recognized.

What to watch next

October 2026
As of January 2026 reporting, the FUEL-2 trial was said to be scheduled to finish in October. Whether the last patient visit and database lock actually land on schedule is the item to verify through company notices and filings.
Fourth quarter of 2026
Whether unblinding and the final p-value on the primary endpoint of peak oxygen uptake are disclosed after trial completion. If, as management describes, the agreed FDA bar is a p-value of 0.1 or below, whether the final figure clears it becomes the premise for the entire subsequent approval process.
Mid-November 2026
The third-quarter 2026 report. Points to check include whether the quarterly operating loss stays in the 4.5 to 5.1 billion won range, and how the capitalized development cost balance, cash holdings and convertible-bond-related liability valuations have changed.
Fourth quarter 2026 through first half 2027
The timing of the new drug application refiling and the review pathway. Progress on the priority review voucher legislation and the outcome of the expedited review program application, both flagged by the company in December 2025, could shape review timelines, so any disclosure of results should be tracked.
March 2027
The 2026 annual and audit reports. How the auditor addresses the key audit matter of recognition and impairment of development costs, listed every year since 2020, and how equity and the debt-to-equity ratio compare with 2025, are the central items.

Overall view

Mezzion is not a company explained by its financial statements.

Reported revenue is roughly 2 billion won a quarter from feed distribution, the operating loss has stayed near 4.5 to 5.1 billion won for five straight quarters, equity shrank from 61.4 billion won in 2023 to 17.2 billion won in 2025, and the debt-to-equity ratio rose to 470.1%.

What the market looks at instead is the confirmatory Phase 3 FUEL-2 for JURVIGO (udenafil) targeting a Fontan population with no FDA-approved therapy and the regulatory steps beyond it.

The bullish case rests on an interim standard deviation below the design assumption, management's account of an agreed bar of a p-value at or below 0.1, and the orphan exclusivity structure.

The bearish case rests on dependence on external funding and dilution, the possibility of impairment on capitalized development costs, and a track record of two failed approval attempts.

On the schedule the company has communicated, the trial is set to conclude in October 2026, so for the next several months discrete events rather than business metrics will supply most of the information. This report is for information purposes and contains no buy or sell opinion and no price target.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.